<SEC-DOCUMENT>0001144204-18-041398.txt : 20180801
<SEC-HEADER>0001144204-18-041398.hdr.sgml : 20180801
<ACCEPTANCE-DATETIME>20180801170234
ACCESSION NUMBER:		0001144204-18-041398
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20180801
DATE AS OF CHANGE:		20180801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226500
		FILM NUMBER:		18985571

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tv498567_s3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and
Exchange Commission on August 1, 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington,&nbsp;D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-3</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv498567_logo01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SYNTHETIC
BIOLOGICS, INC.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact Name of Registrant as Specified
in Its Charter)</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; text-align: center">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nevada</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(State or Other Jurisdiction of</I></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Incorporation or Organization)</I></P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center; font-size: 10pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; text-align: center">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>13-3808303</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(I.R.S. Employer</I></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite
270<BR>
Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734)&nbsp;332-7800</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address, Including Zip Code,
and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Steven A. Shallcross</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Interim Chief Executive Officer
and Chief Financial Officer</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite
270<BR>
Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734)&nbsp;332-7800</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name, Address, Including Zip
Code, and Telephone Number, Including Area Code of Agent for Service)</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>With copies to:</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leslie Marlow, Esq.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hank Gracin, Esq.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Patrick J. Egan, Esq.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gracin &amp; Marlow, LLP</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Chrysler Building</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>405 Lexington Avenue, 26th Floor</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10174</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 907-6457</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate date of commencement of proposed sale to
the public: <B>&nbsp;From time to time after the effective date of this registration statement.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans,
check the following box.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 90%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 69%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Title&nbsp;of&nbsp;each&nbsp;class&nbsp;of<BR> securities&nbsp;to&nbsp;be&nbsp;registered</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount&nbsp;to&nbsp;be</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>registered<SUP>(1)(2)</SUP></B></FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed&nbsp;maximum</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>offering&nbsp;price</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>per&nbsp;share<SUP>(4)</SUP></B></FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed&nbsp;maximum</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>aggregate</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>offering&nbsp;price<SUP>(5)</SUP></B></FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount&nbsp;of<BR> registration&nbsp;fee</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Common Stock, par value $0.001 per share, issuable upon exercise of Warrants</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">25,000,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">1.43</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">35,750,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">4,450.88</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">25,000,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">1.43</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">35,750,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">4,450.88</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule&nbsp;416 under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), this registration statement also covers such additional shares as may hereafter
be offered or issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or certain other capital
adjustments.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Represents shares of common stock underlying warrants issued
to investors in our previous follow-on underwritten public offering.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">No fee pursuant to Rule 457(g) under the Securities Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Represents the per share exercise price of the warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Calculated pursuant to Rule 457(g) under the Securities
Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance
with Section&nbsp;8(a)&nbsp;of the Securities Act or until this Registration Statement shall become effective on such date as the
Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information in
this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with
the Securities and Exchange Commission is effective. This prospectus is not an offer to sell nor does it seek an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>Subject to Completion,
dated August 1, 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv498567_logo01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>25,000,000 Shares of Common Stock
Issuable Upon </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise of Outstanding Warrants&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the offer
and sale by us of an aggregate of 25,000,000 shares of our common stock, par value $0.001 per share, that are issuable at an exercise
price of $1.43 per share from time to time upon the exercise of currently outstanding warrants that we issued in November 2016
as part of an underwritten public offering (the &ldquo;Warrants&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will receive the proceeds from
any cash exercises of the outstanding Warrants. Additionally, the Warrants may be exercised on a cashless basis. If the Warrants
are exercised on a cashless basis, we would not receive any cash payment upon any exercise of the Warrants. Each Warrant is exercisable
at any time until its expiration date, which is November 15, 2020. Upon exercise of all of these outstanding Warrants for cash,
we will receive aggregate proceeds of $35,750,000 for the Warrants. &nbsp;No securities are being offered pursuant to this prospectus
other than the shares of our common stock that will be issued upon exercise of the outstanding Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on
the NYSE American LLC under the symbol &ldquo;SYN.&rdquo; The last reported sale price of our common stock on the NYSE
American LLC on July 31, 2018 was $0.18 per share. We urge prospective purchasers of our common stock to obtain current
information about the market prices of our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INVESTING IN OUR SECURITIES
INVOLVES RISKS. SEE THE &ldquo;RISK FACTORS&rdquo; ON PAGE 6 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE DOCUMENTS
INCORPORATED BY REFERENCE INTO THIS PROSPECTUS CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; line-height: 107%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF OUR SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">DISCLOSURE OF SECURITIES AND EXCHANGE COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES </FONT></A></TD>
    <TD STYLE="text-align: center; line-height: 107%; vertical-align: bottom"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely
only on the information we have provided or incorporated by reference in this prospectus or in any prospectus supplement. We have
not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus
or in any prospectus supplement. This prospectus and any prospectus supplement is an offer to sell only the securities offered
hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information contained
in this prospectus and in any prospectus supplement is accurate only as of their respective dates and that any information we have
incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of
delivery of this prospectus or any prospective supplement or any sale of securities. The registration statement, including the
exhibits and the documents incorporated herein by reference, can be read on the Securities and Exchange Commission website or at
the Securities and Exchange Commission offices mentioned under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus
is not an offer or solicitation in respect to these securities in any jurisdiction in which such offer or solicitation would be
unlawful.&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;).&nbsp;&nbsp;The registration statement that contains this prospectus (including the exhibits to the registration
statement) contains additional information about our company and the securities offered under this prospectus.&nbsp;&nbsp;That
registration statement can be read at the SEC website or at the SEC&rsquo;s offices listed under the heading &ldquo;Where You Can
Find More Information.&rdquo; &nbsp;We have not authorized anyone else to provide you with different information or additional
information.&nbsp;&nbsp;You should not assume that the information in this prospectus, or any supplement or amendment to this prospectus,
is accurate at any date other than the date indicated on the cover page of such documents.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise
stated or the context otherwise requires, references in this prospectus to &ldquo;Synthetic,&rdquo; the &ldquo;Company,&rdquo;
 &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer to Synthetic Biologics, Inc., a Delaware corporation and its consolidated
subsidiaries, unless otherwise specified. When we refer to &ldquo;you,&rdquo; we mean the holders of the applicable series of securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The items
in the following summary are described in more detail elsewhere in this prospectus and in the documents incorporated by reference
herein. This summary provides an overview of selected information and does not contain all the information you should consider
before investing in our securities. Therefore, you should read the entire prospectus and any free writing prospectus that we have
authorized for use in connection with this offering carefully, including the &ldquo;Risk Factors&rdquo; section and other documents
or information included or incorporated by reference in this prospectus before making any investment decision.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Business</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a late-stage
clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients.
Our lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome
from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of <I>C. difficile</I> infection
(CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended
to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome
with constipation (IBS-C). Our preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP)
to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis,
and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tv498567_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">C- Cedars-Sinai Medical Center Collaboration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I- Intrexon Collaboration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T- The University of Texas at Austin Collaboration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M- Scientific collaboration with Massachusetts General Hospital</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary of Clinical and Preclinical Programs</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic Area</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 1%; line-height: 107%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 15%; border-bottom: Black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Candidate</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 1%; line-height: 107%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 63%; border-bottom: Black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade IV beta-lactam antibiotics)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-004 (ribaxamase)</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oral enzyme)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive Phase 1a/1b data (1Q 2015)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive topline data from two Phase 2a clinical trials (4Q 2015 &amp; 2Q 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initiated
        Phase 2b proof-of-concept clinical trial (3Q 2015)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Received
        USAN approval of the generic name &ldquo;ribaxamase&rdquo; for SYN-004 (July 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completed
        Enrollment of Phase 2b proof-of-concept clinical trial (3Q 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awarded
        contract by the CDC (4Q 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced
        positive topline data from Phase 2b proof-of-concept clinical trial, including achievement of primary endpoint of significantly
        reducing CDI (1Q 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced
        additional results from Phase 2b proof-of-concept clinical trial demonstrating SYN-004 (ribaxamase) protected and maintained the
        naturally occurring composition of gut microbes from antibiotic-mediated dysbiosis in treated patients (2Q 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Announced
additional results from Phase 2b proof-of-concept clinical trial funded by a contract awarded by the CDC, demonstrating that SYN-004
(ribaxamase) prevented significant change to the presence of certain AMR genes in the gut resistome of patients receiving SYN-004
compared to placebo (3Q 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Presented
        additional supportive results regarding several exploratory endpoints from Phase 2b proof-of-concept clinical trial designed to
        evaluate SYN-004&rsquo;s (ribaxamase) ability to protect the gut microbiome from opportunistic bacterial infections and prevent
        the emergence of antimicrobial resistance (AMR) in the gut microbiome (4Q 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reached
        preliminary agreement with the FDA on key elements of a proposed Phase 3 clinical trial program, including de-coupled
        co-primary         endpoints designed         to evaluate efficacy separate from safety in a patient population being treated
        with a         representative selection of IV-beta-lactam         antibiotics (1H 2018)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anticipated
        End of Phase 2 meeting with FDA to solidify remaining elements of planned Phase 3 clinical trial (2H 2018)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan
        to initiate Phase 3 clinical trial(s) (2H 2019)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Treatment of IBS-C</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-010</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oral modified-release</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lovastatin lactone)</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 63%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
        with Cedars-Sinai Medical Center</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive topline data from two Phase 2 clinical trials (4Q 2015 &amp; 1Q 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Received
        Type C meeting responses from FDA regarding late-stage aspects of clinical pathway (2Q 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Presented
        detailed data supporting previously reported positive topline data from two Phase 2 clinical trials at DDW (May 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held
        End of Phase 2 meeting with FDA (July 2016)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confirmed
        key elements of Pivotal Phase 2b/3 clinical trial design pursuant to consultations with FDA (1Q 2017)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-left: 20.7pt; text-align: justify; line-height: 107%; text-indent: -20.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced issuance of key U.S. composition of matter patent providing important intellectual property protection in the U.S until at least 2035 (Q2 2018)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade IV carbapenem antibiotics)</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SYN-006</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(oral enzyme)</P></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identified
        P2A as a potent carbapenemase that is stable in the GI tract</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufactured
        and formulated research lot for oral delivery (2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demonstrated
        microbiome protection in a pig model if ertapenem administration (Q1 2018)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; line-height: 107%; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade oral beta-lactam antibiotics)&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-007</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oral enzyme)</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; line-height: 107%; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical work ongoing to expand the utility of SYN-004 (ribaxamase) for use with oral beta-lactam antibiotics</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; line-height: 107%; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preserve gut barrier, treat local GI inflammation, restore gut microbiome</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-020</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oral IAP enzyme)</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generated
        high expressing manufacturing cell lines for intestinal alkaline phosphatase (IAP) (1H 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identified
        downstream process and potential tablet formulations (2H 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ongoing
        preclinical efficacy studies</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention and treatment of pertussis</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-005</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(monoclonal antibody</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">therapies)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive preclinical research findings (2014)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
        University of Texas at Austin (&ldquo;UT Austin&rdquo;) received a grant from the Bill and Melinda Gates Foundation to support
        a preclinical study to evaluate the prophylactic capability of SYN-005 (4Q 2015)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive preclinical data demonstrating hu1B7, a component of SYN-005, provided protection from pertussis for five weeks in neonatal
        non-human primate study (Q2 2017)&nbsp;</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive preclinical data demonstrating that an extended half-life version of hu1B7, a component of SYN-005, provided protection
        from pertussis for five weeks in a non-human neonatal primate study (Q4 2017)</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborations
        with Intrexon and UT Austin</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Microbiome-Focused Pipeline</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CDI and
IBS-C programs are focused on protecting the healthy function of the gut microbiome, or gut flora, which is composed of billions
of microbial organisms including a natural balance of both &ldquo;good&rdquo; beneficial species and potentially &ldquo;bad&rdquo;
pathogenic species. When the natural balance or normal function of these microbial species is disrupted, a person&rsquo;s health
can be compromised. All of our programs are supported by our growing intellectual property portfolio. We are maintaining and building
our patent portfolio through: filing new patent applications; prosecuting existing applications; and licensing and acquiring new
patents and patent applications. Our plan remains focused on the advancement of our two late-stage clinical programs. We continue
to actively manage resources in preparation for the late-stage clinical advancement of our two lead microbiome-focused clinical
programs, including our pursuit of successful and viable opportunities that will allow us to establish the clinical infrastructure
and financial resources necessary to successfully initiate and complete this plan.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our predecessor, Sheffield
Pharmaceuticals, Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware
corporation formed in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed
our name to Adeona Pharmaceuticals, Inc. On October 15, 2009, we engaged in a merger with a wholly owned subsidiary for the purpose
of reincorporating in the State of Nevada. After reprioritizing our focus on the emerging area of synthetic biologics and entering
into our first collaboration with Intrexon, we amended our Articles of Incorporation to change our name to Synthetic Biologics,
Inc. on February 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive offices
are located at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850. Our telephone number is (732) 332-7800, and our
website address is <I>www.syntheticbiologics.com</I>. The information contained on our website is not part of, and should not be
construed as being incorporated by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Common stock offered by us&nbsp;pursuant</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">to this prospectus</P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000,000 shares of common stock that are issuable at an exercise price of $1.43 per share from time to time until November 15, 2020 upon the exercise of currently outstanding warrants that we issued in November 2016 as part of an underwritten public offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Common stock to be outstanding&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">after this offering if all of the&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Warrants are exercised</P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,969,743
    shares<SUP>(1)</SUP></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use the net proceeds, if any, from this offering for general corporate purposes, which may include, among other things, for clinical trials for our product candidates, paying general and administrative expenses and accounts payable, increasing our working capital, funding research and development and funding capital expenditures. We may also use a portion of the net proceeds for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development programs and to in-license, acquire or invest in complementary businesses or products, although we have no commitments or agreements with respect to any such licenses, acquisitions or investments as of the date of this prospectus. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;Risk Factors&rdquo; beginning on page 6 of this prospectus and the other information included in, or incorporated by
    reference into, this prospectus for a discussion of certain factors you should carefully consider before deciding to invest
    in shares of our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American, LLC Symbol</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SYN&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The number of shares of
common stock shown above to be outstanding after this offering is based on 132,969,743 shares of our common stock outstanding
as of July 31, 2018, which does not include the following, all as of July 31, 2018:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,168,515
shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $1.55 per share;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,973,607
shares of common stock which were reserved for future equity awards that may be granted in the future under our equity incentive
plans; </FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">22,579,789 shares of our common stock issuable upon conversion of outstanding shares of
                                                                                                preferred stock (the &ldquo;Preferred Stock Shares&rdquo;); and</TD>
</TR></TABLE>







<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,054,808 shares
                                                                                                                                                  of
                                                                                                                                                  our common stock reserved for issuance upon the exercise of outstanding warrants, of which 7,029,809 have an exercise price
                                                                                                                                                  of
                                                                                                                                                  $1.75 per share (the &ldquo;2014 Warrant Shares&rdquo;) and 25,000 have an exercise price of $0.52 per share (the &ldquo;2017 Warrant Shares&rdquo;).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>You should
consider carefully the risks discussed under the section captioned &ldquo;Risk Factors&rdquo; contained in our most recent annual
report on Form 10-K and in our subsequent quarterly reports on Form 10-Q, as updated by our subsequent filings under the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), all of which we incorporate by reference herein, together with
other information in this prospectus, and the information and documents incorporated by reference herein before you make a decision
to invest in our common stock. If any of these events actually occur, our business, operating results, prospects or financial condition
could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose
all or part of your investment.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the
statements contained or incorporated by reference in this prospectus may include forward-looking statements that reflect our current
views with respect to our ongoing and planned clinical trials, business strategy, business plan, financial performance and other
future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology
sector, in general. We make these statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Statements that include the words &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;will&rdquo;
and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities
laws or otherwise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All
forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could
cause actual results to differ materially from those indicated in these statements. We believe that these factors include,
but are not limited to, those factors set forth under the caption &ldquo;Risk Factors&rdquo; in this prospectus and under the
captions &ldquo;Risk Factors,&rdquo;  &ldquo;Business,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations,&rdquo; in our most recent Annual Report on Form&nbsp;10-K and our subsequent
Quarterly Reports on Form 10-Q, all of which you should review carefully. Please consider our forward-looking statements in
light of those risks as you read this prospectus supplement and the accompanying prospectus. We undertake no obligation to
publicly update or review any forward-looking statement, whether as a result of new information, future developments or
otherwise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If one or more
of these or other risks or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may
vary materially from what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals
acting on our behalf are expressly qualified in their entirety by this Note. Before purchasing any of our securities, you should
consider carefully all of the factors set forth or referred to in this prospectus that could cause actual results to differ.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If all of the
outstanding Warrants are exercised, we estimate that the proceeds of this offering will be approximately $35,750,000 for the
exercise of the Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds
from any disposition of the shares of common stock covered hereby would be received by the investors selling such shares. We will
not receive any of the proceeds from any such sale of the common stock offered by this prospectus other than the net proceeds of
any Warrants exercised for cash. Additionally, the Warrants may be exercised on a cashless basis. If the Warrants are exercised
on a cashless basis, we would not receive any cash payment upon any exercise of the Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to
use any proceeds that we do receive from the exercise of Warrants for general corporate purposes, which may include, among other
things, for clinical trials for our product candidates, paying general and administrative expenses and accounts payable, increasing
our working capital, funding research and development and funding capital expenditures. We may also use a portion of the net proceeds
for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development
programs and to in-license, acquire or invest in complementary businesses or products, although we have no commitments or agreements
with respect to any such licenses, acquisitions or investments as of the date of this prospectus.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts
and timing of our actual expenditures will depend on numerous factors, including our development and commercialization efforts,
as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to
be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and
we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net
proceeds from this offering in short-term, investment-grade, interest-bearing securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest
in our common stock, your interest will be diluted immediately to the extent of the difference between the offering price and the
adjusted net tangible book value per share of our common stock after this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net tangible
book value on March 31, 2018 was approximately $7.0 million, or $0.054 per share. &ldquo;Net tangible book value&rdquo; is total
assets minus the sum of liabilities and intangible assets. &ldquo;Net tangible book value per share&rdquo; is net tangible book
value divided by the total number of shares outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After
giving effect to the sale of an aggregate of 25,000,000 shares of common stock to investors exercising Warrants for aggregate
cash net  proceeds of $35,715,000 and after taking into account expenses of this offering and the sale of 4,402,857 shares
subsequent to March 31, 2018 through July 31, 2018 for proceeds of $1,000,103, our pro forma as adjusted net tangible
book value as of March 31, 2018 would have been approximately $43,718,103 million, or $0.28 per share of common stock.
This represents an immediate increase in the pro forma net tangible book value of $0.22 per share to our existing
stockholders and an immediate dilution in net tangible book value of $1.15 per share to investors participating in this
offering. The following table illustrates this dilution per share to investors participating in this offering:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.25in">Exercise price per share</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.43</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-indent: -0.25in">Pro forma net tangible book value per share as of March 31, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.06</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in; text-indent: -0.25in">Increase in pro forma net tangible book value per share attributable to this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.22</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.25in">Pro forma as adjusted net tangible book value per share after giving effect to this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.28</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; text-indent: -0.25in">Dilution per share to investors purchasing our common stock in this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.15</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above
discussion and table are based on 128,648,366 shares of our common stock outstanding as of March 31, 2018 (as adjusted to take
into account 4,402,857 shares of common stock issued subsequent to March 31, 2018 through July 31, 2018 and the issuance of
the 25,000,000 shares of common stock upon exercise of the Warrants), which does not include the following, all as of
March 31, 2018:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,564,098
shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $1.55 per share;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,054,808 shares of
                                                                                                                                                  our common stock reserved for issuance upon the exercise of outstanding warrants, of which 7,029,809 have an exercise
                                                                                                                                                  price of $1.75 per share and 25,000 have an exercise price of $0.52 per share; </FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">5,973,607 shares of common stock which were reserved for future equity awards that may be
    granted in the future under our equity incentive plans; and</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">shares of our common stock
                                                                                                issuable upon conversion of outstanding shares of preferred stock.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that any
outstanding options are exercised, the 2014 Warrant Shares or the 2017 Warrant Shares are issued, the preferred stock shares
are issued or we issue additional shares under our equity incentive plans, there will be further dilution to new investors.
In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we
believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised
through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution
to our stockholders.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never paid cash dividends on our common stock. Moreover, we do not anticipate paying periodic cash dividends on our common
stock for the foreseeable future. We intend to use all available cash and liquid assets in the operation and growth of our business.
Any future determination about the payment of dividends will be made at the discretion of our board of directors and will be subject
to the rights of any outstanding preferred stock and will depend upon our earnings, if any, capital requirements, operating and
financial conditions and on such other factors as our board of directors deems relevant. The Series A Preferred Stock ranks senior
to the shares of our common stock with respect to dividend rights and holders of Series A Preferred Stock are entitled to a cumulative
dividend at the rate of 2.0%&nbsp;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series
A Convertible Preferred Stock</FONT>.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>DESCRIPTION OF OUR SECURITIES</B></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following is a summary of the rights of our common stock and preferred stock and related provisions of our articles of
incorporation and bylaws. For more detailed information, please see our articles of incorporation and bylaws.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Authorized Capital</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
authorized capital consists of 350 million shares of common stock, par value $0.001 per share, and 10 million shares of
preferred stock, par value $0.001 per share. As of July 31, 2018, 132,969,743 shares of common stock were issued and
outstanding, and 120,000 shares of preferred stock were issued and outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue
shares of our common stock from time to time. We currently have authorized 350,000,000 shares of common stock, par value $.001
per share. We may offer shares of common stock alone or underlying the registered securities convertible into or exercisable for
our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting.&nbsp;
</I>The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of
the stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a
majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing
for election.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividends.&nbsp;
</I>Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled
to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation.</I>&nbsp;
In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the
net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject
to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Rights and
Preferences.</I>&nbsp; The holders of our common stock have no preemptive, conversion or subscription rights, and there are no
redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of
our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred
stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Fully Paid
and Nonassessable</I>.&nbsp; All of our outstanding shares of common stock are, and the shares of common stock to be issued under
this prospectus will be, fully paid and nonassessable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this
prospectus, we have summarized certain general features of our common stock under &ldquo;Description of Our Securities&mdash;Common Stock.&rdquo; We urge you, however, to read the applicable prospectus supplement (and any related free writing
prospectus that we may authorize to be provided to you) related to any common stock being offered.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of
Directors has the authority, without action by our stockholders, to designate and issue up to 10 million shares of preferred stock
in one or more series or classes and to designate the rights, preferences and privileges of each series or class, which may be
greater than the rights of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred
stock upon the rights of holders of our common stock until our Board of Directors determines the specific rights of the holders
of the preferred stock. However, the effects might include:&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricting
dividends on our common stock;</FONT></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting
the voting power of our common stock;</FONT></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing
liquidation rights of our common stock; or</FONT></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying
or preventing a change in control of us without further action by our stockholders.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of
Directors&rsquo; authority to issue preferred stock without stockholder approval could make it more difficult for a third-party
to acquire control of our company, and could discourage such attempt. We have no present plans to issue any shares of preferred
stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series A Preferred</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had 120,000
shares of Series A Preferred Stock outstanding as of the date of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series
A Preferred Stock ranks senior to the shares of our common stock, and any other class or series of stock issued by us with
respect to dividend rights, redemption rights and rights on the distribution of assets on our voluntary or involuntary
liquidation, dissolution or winding up. Holders of Series A Preferred Stock are entitled to a cumulative dividend at the rate
of 2.0%&nbsp;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Preferred
Stock classifying the Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at
any time into shares of common stock based upon its Accreted Value (as defined below) at an initial conversion price of $0.54 per share, subject to certain customary anti-dilution
adjustments.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any conversion
of Series A Preferred Stock may be settled by us in shares of common stock only.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holder&rsquo;s
ability to convert the Series A Preferred Stock into common stock is subject to (i)&nbsp;a 19.99% blocker provision to comply with
NYSE American Listing Rules, (ii)&nbsp;if so elected by the holder, a 4.99% blocker provision that will prohibit beneficial ownership
of more than 4.99% of our outstanding shares common stock or voting power at any time, and (iii)&nbsp;applicable regulatory restrictions.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
the event of our liquidation, dissolution or winding-up, holders of the Series A Preferred Stock are entitled to a preference
on liquidation equal to the greater of (i) an amount per share equal to the original issue price plus any accrued and unpaid
dividends on such share of Series A Preferred Stock (the &ldquo;Accreted Value&rdquo;), and (ii) the amount such holders
would receive in such liquidation if they converted their shares of Series A Preferred Stock (based on the Accreted Value and
without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation,
dissolution or winding-up (the greater of (i) and (ii), is referred to as the &ldquo;Liquidation Value&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise
required by law, the holders of Series A Preferred Stock have no voting rights, other than customary protections against adverse
amendments and issuance of&nbsp;<I>pari passu</I>&nbsp;or senior preferred stock. Upon certain change of control events involving
our company, we will be required to repurchase all of the Series A Preferred Stock at a redemption price equal to the greater of
(i) the Accreted Value, and (ii) the amount that would be payable upon a change of control (as defined in the Certificate of Designation)
in respect of common stock issuable upon conversion of such share of Series A Preferred Stock if all outstanding shares of Series
A Preferred Stock were converted into common stock immediately prior to the change of control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On or at any
time after (i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period
is greater than $2.00, subject to adjustment in the case of stock split, stock dividends or the like we have the right, after providing
notice not less than 6 months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders
thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred Stock, for cash,
at a redemption price per share of Series&nbsp;A Preferred Stock of $225.00, subject to appropriate adjustment in the event of
any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Preferred
Stock, or (ii) the five year anniversary of the issue date, we have the right to redeem, in whole or in part, on a pro rata basis
from all holders thereof based on the number of shares of Series A Convertible Preferred Stock then held, the outstanding Series
A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31,
2018, we had issued and outstanding a total of 32,054,809 warrants to purchase our common stock outstanding at a weighted-average
price of $1.50.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Warrants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November
18, 2016, we completed a public offering of 25,000,000 shares of common stock in combination with accompanying warrants to purchase
an aggregate of 50,000,000 shares of the common stock, of which warrants to purchase 25,000,000 shares of common stock are outstanding.
The initial per share exercise price of the Warrants is $1.43, subject to adjustment as specified in the warrant agreement. The
Warrants may be exercised at any time until the four-year anniversary of the issuance date (November 18, 2020). </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to
the terms of the Warrant, a holder of a Warrant will not have the right to exercise any portion of the Warrant if the holder (together
with its affiliates) would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrant provided
that at the election of a holder and notice to us such percentage ownership limitation shall be 4.99% of the number of shares of
common stock outstanding immediately after giving effect to the exercise. However, any holder may increase or decrease such percentage
to any other percentage not in excess of 9.99% upon at least 61 days&rsquo; prior notice from the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at the time a holder
exercises its Warrant there is no effective registration statement registering, or the prospectus contained therein is not available
for an issuance of the shares underlying the Warrant to the holder, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such
exercise (either in whole or in part) the net number of shares of our common stock determined according to a formula set forth
in the Warrant. In the event of a cashless exercise, if we fail to timely deliver the shares underlying the Warrants, we will be
subject to certain buy-in provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any
extraordinary transaction, as described in the Warrants and generally including any merger with or into another entity, sale of
all or substantially all of our assets, tender offer or exchange offer, or reclassification of our common stock, the holder will
have the right to have the Warrants and all obligations and rights thereunder assumed by the successor or acquiring corporation.
In the event of an extraordinary transaction, we or any successor entity will pay at the holder&rsquo;s option, exercisable at
any time concurrently with or within 30 days after the consummation of the extraordinary transaction, an amount of cash equal to
the value of the Warrant as determined in accordance with the Black Scholes option pricing model and the terms of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable
laws and the restriction on transfer set forth in the Warrant, the Warrant may be transferred at the option of the holder upon
surrender of the Warrant to us together with the appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no
established public trading market for the Warrants, and we do not expect a market to develop. In addition, we have not applied
to list the Warrants on any securities exchange or recognized trading system.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>October 2014 Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 10,
2014, we issued 14,059,616 units at a price of $1.47 per unit to certain institutional investors in a registered direct offering,
each unit consisted of one share of our common stock and a warrant to purchase 0.5 shares of common stock (the &ldquo;October 2014
warrants&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July
31, 2018, we had issued and outstanding October 2014 Warrants that are exercisable for a total of 7,029,808 shares of common stock.
Below is a summary of the October 2014 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each
October 2014 warrant is exercisable at any time after the closing date (October 10, 2014) and expires in five years after
issuance (October 10, 2019). The October 2014 Warrants are exercisable, at the option of each holder, in whole or in part by
delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased
upon such exercise, except in the case of a cashless exercise as discussed below.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holder
may exercise the October 2014 Warrant on a cashless basis. When exercised on a cashless basis, a portion of the October
2014 Warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock
purchasable upon such exercise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each
October 2014 Warrant represents the right to purchase up to one half of a&nbsp;share of common stock at an exercise price
of $1.75 per share. The exercise price per share is subject to adjustment for stock dividends, distributions,
subdivisions, combinations, or reclassifications. Subject to limited exceptions, a holder of October 2014 Warrants will not
have the right to exercise any portion of the  October 2014 Warrant to the extent that, after giving effect to the exercise,
the holder, together with its affiliates, would beneficially own in excess of 4.99% or 9.99%, depending on the holder&rsquo;s
initial election, of the number of shares of our common stock outstanding immediately after giving effect to its exercise.
The holder may elect to increase or decrease this beneficial ownership limitation to any other percentage, but not in excess
of 19.9% of the total number of issued and outstanding shares of common stock (including for such purpose the shares of
common stock issuable upon such exercise), provided that any such increase or decrease will not be effective until 61 days
after such written notice is delivered.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the
event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers,
reclassification or share exchange in which our common stock is effectively converted into or exchanged for other securities,
cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our
common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented
by our issued and outstanding common stock (a &ldquo;Fundamental Transaction&rdquo;), then, upon any subsequent exercise of
the October 2014 Warrants, the holders of October 2014 Warrants will have the right to receive any shares of the acquiring
corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of
common stock then issuable upon exercise in full of the October 2014 Warrants. Except in connection with a Fundamental
Transaction in which the consideration for each share of common stock is at least 300% of the exercise price of the October
2014 Warrant, we or the successor entity will, at the holder&rsquo;s option, purchase the unexercised portion of the October
2014 Warrant from the holder (i) in the case of an all cash transaction or a transaction in which the consideration consists
partially of cash or securities of a successor entity to the extent of the percentage of the cash consideration, for an
amount of cash equal to equal to the Black-Scholes value of the remaining unexercised portion of the October 2014 Warrant on
the date of the consummation of the transaction and (ii) in the case of any other Fundamental Transaction or in a transaction
in which the consideration consists partially of cash or securities of a successor entity to the extent the consideration is
represented by securities, for a number of shares of common stock equal to the Black Scholes value of the portion of the
warrant subject to redemption divided by 95% of the closing sale price of the common stock on the day preceding the date on
which the Fundamental Transaction is consummated.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to
applicable laws and restrictions, a holder may transfer an October 2014 Warrant upon surrender of the October 2014 Warrant to
us with a completed and signed assignment in the form attached to the October 2014 Warrant. The transferring holder will
be responsible for any tax that liability that may arise as a result of the transfer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is
no established public trading market for the October 2014 Warrants, and we do not expect a market to develop. In addition, we
have not applied to list the October 2014 Warrants on any securities exchange or recognized trading system.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>December
2017 Warrants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On
December 26, 2017, we issued warrants to purchase 25,000 shares of our common stock as consideration for advisory
services. The December 2017 Warrants have an exercise price of $0.52 and expire December 26, 2022. The exercise price is
subject to stock dividends, distributions, subdivisions, combinations or reclassifications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There
is no established public trading market for the December 2017 Warrants and we do not expect a market to develop. In addition,
we have not applied to list the December 2017 Warrants on any securities exchange or recognized trading system.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>Options</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of
July 31, 2018, options to purchase an aggregate of
12,168,515 shares of common stock were
outstanding under our equity incentive plans.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock
referenced on the cover page&nbsp;of this prospectus will be offered solely by us and will be issued and sold upon the exercise
of the outstanding Warrants described in this prospectus. We will deliver shares of our common stock upon exercise of the warrants,
however, no fractional shares will be issued. The Warrants are exercisable for a total of 25,000,000 shares of our common stock
(subject to adjustment), and no more of these warrants will be issued by us. Each of the Warrants contains instructions for exercise.
In order to exercise any of the Warrants, the holder must deliver to us or our transfer agent the information required in the Warrants,
along with payment for the exercise price of the shares of common stock to be purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gracin &amp; Marlow,
LLP, New York, New York will pass upon certain legal matters related to the issuance and sale of the Warrants offered on our behalf
and Parsons Behle &amp; Latimer, Reno, Nevada will pass upon certain legal matters relating to the issuance and sale of the common
stock offered hereby on our behalf.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
of Synthetic Biologics, Inc. as of December 31, 2017 and 2016 and for each of the three years in the period ended December
31, 2017 and management&rsquo;s assessment of the effectiveness of internal control over financial reporting as of December 31,
2017 incorporated by reference in this prospectus have been so incorporated in reliance on the reports of BDO USA, LLP, an independent
registered public accounting firm, incorporated herein by reference, given on authority of said firm as experts in auditing and
accounting. The report on the financial statements contains an explanatory paragraph regarding our ability to continue as a going
concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and special reports, proxy statements and other information with the SEC. You may read and copy any document we file at the SEC&rsquo;s
public reference room located at 100 F Street N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information
on the operation of the public reference room. Our public filings are also available to the public at the SEC&rsquo;s web site
at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is
part of a registration statement on Form S-3 that we have filed with the SEC under the Securities Act. This prospectus does not
contain all of the information in the registration statement. We have omitted certain parts of the registration statement, as permitted
by the rules and regulations of the SEC. You may inspect and copy the registration statement, including exhibits, at the SEC&rsquo;s
public reference room or Internet site.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A><B>INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows
us to &ldquo;incorporate by reference&rdquo; the information we file with it which means that we can disclose important information
to you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated
by reference is considered to be part of this prospectus, and later information that we file with the SEC will automatically update
and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC
(other than any portions of any such documents that are not deemed &ldquo;filed&rdquo; under the Exchange Act in accordance with
the Exchange Act and applicable SEC rules) under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after (i) the date of the
initial registration statement and prior to the effectiveness of the registration statement, and (ii) the date of this prospectus
and before the completion of the offerings of the securities included in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
annual report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on February 22, 2018 (File No. 001-12584);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
quarterly report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 8, 2018 (File No. 001-12584);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current reports on Form 8-K (File No. 001-12584) filed with the SEC on January 8, 2018, March 7, 2018; April 23, 2018, May 7,
2018 and May 22, 2018;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
definitive proxy statement on Schedule 14A filed with the SEC on July 18, 2017 (File No. 001-12584); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of our common stock set forth in our registration statement on Form 8-A12B, filed with the SEC on June 20, 2007 (File
No. 000-12584).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained
in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed
to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any
other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the
statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will furnish without
charge to you, on written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus
but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents.
You should direct any requests for documents to Synthetic Biologics, Inc., Attn: Steven A. Shallcross, Interim Chief Executive
Officer and Chief Financial Officer, 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850, or telephoning us at (301)
417-4364.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only
on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference in this prospectus. We are not making
offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person
making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><B>DISCLOSURE OF SECURITIES AND EXCHANGE
COMMISSION POSITION ON INDEMNIFICATION<BR>
FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
bylaws and Articles of Incorporation contain provisions that permit us to indemnify our directors and officers to the full extent
permitted by Nevada law, and our Articles of Incorporation, as amended, contains provisions that eliminate the personal liability
of our directors in each case for monetary damages to us or our stockholders for breach of their fiduciary duties, except to the
extent that Nevada law prohibits indemnification or elimination of liability. These provisions do not limit or eliminate our rights
or the rights of any stockholder to seek an injunction or any other non-monetary relief in the event of a breach of a director&rsquo;s
or officer&rsquo;s fiduciary duty. In addition, these provisions apply only to claims against a director or officer arising out
of his or her role as a director or officer and do not relieve a director or officer from liability if he or she engaged in willful
misconduct or a knowing violation of the criminal law or any federal or state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights of indemnification
provided in our amended and restated bylaws are not exclusive of any other rights that may be available under any insurance or
other agreement, by vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to
the foregoing provisions, we have been informed that in the opinion of the SEC this type of indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                          14.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Expenses of Issuance and Distribution.</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following
table sets forth the estimated fees and expenses in connection with the shelf registration of the common stock registered under
this registration statement. The actual amounts of such fees and expenses will be determined from time to time. All amounts shown
are estimates except for the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) registration fee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">SEC registration fee</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,451</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Miscellaneous expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,549</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">35,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                          15.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnification
of Directors and Officers.</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 78.138
of the Nevada Revised Statute provides that a director or officer is not individually liable to the corporation or its stockholders
or creditors for any damages as a result of any act or failure to act in his capacity as a director or officer unless it is proven
that (1) his act or failure to act constituted a breach of his fiduciary duties as a director or officer and (2) his breach of
those duties involved intentional misconduct, fraud or a knowing violation of law.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This provision
is intended to afford directors and officers protection against and to limit their potential liability for monetary damages resulting
from suits alleging a breach of the duty of care by a director or officer. As a consequence of this provision, stockholders of
our company will be unable to recover monetary damages against directors or officers for action taken by them that may constitute
negligence or gross negligence in performance of their duties unless such conduct falls within one of the foregoing exceptions.
The provision, however, does not alter the applicable standards governing a director&rsquo;s or officer&rsquo;s fiduciary duty
and does not eliminate or limit the right of our company or any stockholder to obtain an injunction or any other type of non-monetary
relief in the event of a breach of fiduciary duty.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant&rsquo;s
Articles of Incorporation, as amended, and amended and restated bylaws provide for indemnification of directors, officers, employees
or agents of the Registrant to the fullest extent permitted by Nevada law (as amended from time to time).&nbsp;&nbsp;Section 78.7502
of the Nevada Revised Statute provides that such indemnification may only be provided if the person acted in good faith and in
a manner he or she reasonably believed to be in, or not opposed to, the best interest of the Registrant and, with respect to any
criminal action or proceeding, had no reasonable cause to behave his conduct was unlawful.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                          16.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exhibits.</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="width: 1%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 94%; padding: 0; text-align: justify; text-indent: 0">Certificate
    of Incorporation, as amended (Incorporated by reference to <A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016308000665/s11-8824_ex31.htm" STYLE="-sec-extract: exhibit">(i)
    Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on October 16, 2008) (File No.
    001-12584)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/894158/000095012401502861/c64437ex3-1.txt" STYLE="-sec-extract: exhibit">(ii)
    Exhibit 3.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2001 filed with
    the SEC on August 14, 2001 (File No. 001-12584)</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/894158/0000921895-98-000694.txt" STYLE="-sec-extract: exhibit">(iii) Exhibits 3.1,
    4.1 and 4.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 1998 filed with the SEC on August 14, 1998 (File No. 001-12584).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Merger (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on October 19, 2009) (File No. 001-12584).&nbsp;&nbsp;</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit 3.2 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on October 19, 2009) (File No. 001-12584). </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit 3.3 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on October 19, 2009) (File No. 001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420411060729/v238878_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420411060729/v238878_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws Adopted and Effective October 31, 2011 (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on November 2, 2011) (File No. 001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420412009508/v302955_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420412009508/v302955_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on February 16, 2012) (File No. 001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420415031962/v411020_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420415031962/v411020_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on May 18, 2015) (File No. 001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations for Series A Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on September 12, 2017)(File No. 001-12584)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420417047316/v474831_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420417047316/v474831_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed with the SEC on September 8, 2017) (File No. 001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420413038075/v348628_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420413038075/v348628_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Stock Certificate evidencing shares of Common Stock (Incorporated by reference to Exhibit 4.1 of Registrant&rsquo;s registration statement on Form S-3 filed with the SEC on July 3, 2013) (File No. 333-189794).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420416134769/v453193_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420416134769/v453193_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to purchase shares of common stock (Incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed with the SEC on November 15, 2016) (File No. 0001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420416134769/v453193_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/894158/000114420416134769/v453193_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agreement (Incorporated by reference to (Incorporated by reference to Exhibit 4.3 of our Current Report on Form 8-K filed with the SEC on November 15, 2016) (File No. 0001-12584).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1(a)</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal opinion of Parsons Behle &amp; Latimer*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal opinion of Gracin &amp; Marlow, LLP&nbsp;*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm (BDO USA, LLP)*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Parsons Behle &amp; Latimer (included in Exhibit 5.1(a))*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv498567_ex5-1b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Gracin &amp; Marlow, LLP (included in Exhibit 5.1(b))*&nbsp;</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#poa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#poa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers of Attorney for our directors (included on signature page)*</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                          17.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Undertakings</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) To include
any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) To reflect
in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in
the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii) To include
any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement; <I><U>provided</U>, <U>however</U></I> , that the undertakings
set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section
13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement or
is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the registration statement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) That, for
the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) That, for
the purpose of determining liability under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) Each prospectus
filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the
filed prospectus was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) Each prospectus
required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that
is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to
the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. <I><U>Provided</U>, <U>however</U></I>, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such effective date; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii) Each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the
registration statement as of the date it is first used after effectiveness<I>; <U>provided</U>, <U>however</U>,</I> that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: justify; text-indent: 17.25pt">&nbsp;(6)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">The undersigned
registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">(i) Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">(ii) Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">(iv) Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: justify; text-indent: 17.25pt">(b) That,
for purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant
to section 13(a) or section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: justify; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: justify; text-indent: 17.25pt">(h) Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant
of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-indent: 17.25pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">(5) That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser
and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">(i) Any preliminary prospectus or
prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">(ii) Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">(iii) The portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities
provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iv) Any other
communication that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp; The undersigned registrant
hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s
annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of
an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated
by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant
of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act of 1933 and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of
the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form&nbsp;S-3 and has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, August 1, 2018.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SYNTHETIC BIOLOGICS, INC.</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 50%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 5%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 45%; line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="line-height: 107%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer and </FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer, Principal </FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Officer and Principal Accounting Officer) &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="poa"></A><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, the undersigned hereby severally
constitute and appoint Steven A. Shallcross our true and lawful attorney and agent, with full power to sign for us, and in our
names in the capacities indicated below, any and all amendments to this registration statement, any subsequent registration statements
pursuant to Rule 462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents
in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each
of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that
said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power
of attorney may be executed in counterparts.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of
the Securities Act 1933, this report has been signed by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross &nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 46%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer and Chief Financial Officer</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right; line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
1, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Jeffrey J. Kraws</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
1, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey J. Kraws</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Scott L. Tarriff</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">August 1, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott L. Tarriff</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey Wolf</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">August 1, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Wolf</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1A
<SEQUENCE>2
<FILENAME>tv498567_ex5-1a.htm
<DESCRIPTION>EXHIBIT 5.1A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 5.1(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">GRACIN &amp; MARLOW, LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The Chrysler Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">405 Lexington Avenue, 26th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">New York, New York 10174</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Telephone (212) 907-6457</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Facsimile: (212) 208-4657</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: center; text-indent: 0.5in">August
1, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9605 Medical Center Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Synthetic
Biologics, Inc. Form S-3</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Gentlemen:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Synthetic
Biologics, Inc., a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with its filing on the date hereof
with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) of a registration statement on Form S-3
(as amended, the &ldquo;<B><I>Registration Statement</I></B> &rdquo;), covering the offer and sale of the following securities:
(i) warrants to purchase up to 25,000,000 shares of Common Stock that were issued to investors on November 18, 2016 in an underwritten
public offering (the &ldquo;<B><I>Warrants</I></B>&rdquo;), and (ii) the 25,000,000 shares of Common Stock issuable upon exercise
of the Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is being furnished
in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As such counsel, we have
examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your
consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters
without having independently verified such factual matters. We are opining herein as to the laws of the State of New York,
and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other
jurisdiction or any other laws, or as to any matters of municipal law or the laws of any local agencies within any state.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the foregoing and the
other matters set forth herein, it is our opinion that, as of the date hereof:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants constitute a valid
and binding agreement of the Company enforceable against the Company in accordance with its terms, subject to applicable bankruptcy,
insolvency, fraudulent conveyance, moratorium and similar laws affecting creditors&rsquo; rights generally and equitable principles
of general applicability.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is for your benefit
in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to
the applicable provisions of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;). We consent
to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm contained in the prospectus
that forms a part of the Registration Statement under the heading &ldquo;Legal Matters.&rdquo; In giving such consent, we do not
thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations
of the Commission thereunder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 50%; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD>
    <TD STYLE="width: 50%; line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Gracin &amp; Marlow, LLP</I></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1B
<SEQUENCE>3
<FILENAME>tv498567_ex5-1b.htm
<DESCRIPTION>EXHIBIT 5.1B
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 5.1(b)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><IMG SRC="tv498567_ex5-1bimg01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"> August 1, 2018</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">9605 Medical Center Drive</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Suite 270</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Synthetic
Biologics, Inc. Registration Statement on Form S-3</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gentlemen:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Synthetic
Biologics, Inc., a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with its filing on the date hereof
with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) of a registration statement on Form S-3
(as amended, the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), covering the offer and sale of the following securities:
(i) warrants to purchase up to 25,000,000 shares of Common Stock that were issued to investors on November 18, 2016 in an underwritten
public offering (the &ldquo;<B><I>Warrants</I></B>&rdquo;), and (ii) the 25,000,000 shares of Common Stock issuable upon exercise
of the Warrants (the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is being furnished
in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;), and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement
or the prospectus that forms a part of the Registration Statement (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), other than as expressly
stated herein with respect to the issuance of the Warrants and the Warrant Shares. In that regard, our opinion is limited to issuances
of the Warrant Shares, since the Company has obtained the opinion of a different firm with respect to the Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As such counsel, we have examined
such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we
have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently
verified such factual matters. We are opining herein as to the Nevada Revised Statutes (the &ldquo;<B><I>NRS</I></B>&rdquo;), and
we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or,
in the case of Nevada, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion,
we have examined and relied upon the representations and warranties as to factual matters contained in and made pursuant to the
Registration Statement, and upon such other documents as in our judgment are necessary or appropriate to enable us to render the
opinions expressed herein.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our knowledge of the Company and
its legal and other affairs is limited by the scope of our engagement, which scope includes the delivery of this opinion letter.
We do not represent the Company with respect to all legal matters or issues. The Company may employ other independent counsel and,
to our knowledge, handles certain matters and issues without the assistance of independent counsel.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our examination of the foregoing,
we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements, instruments
and other documents submitted to us; (ii) the legal capacity and authority of all persons or entities executing all agreements,
instruments and other documents submitted to us; (iii) the authenticity and completeness of all agreements, instruments, corporate
records, certificates and other documents submitted to us as originals; (iv) that all agreements, instruments, corporate records,
certificate and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform
to authentic originals thereof, and that such originals are authentic and complete; (v) the due authorization, execution and delivery
of all instruments, agreements, and other documents by the parties thereto; (vi) that the statements contained in the certificates
and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied
for the purposes of this letter are true and correct; and (vii) that the officers and directors of the Company have properly exercised
their fiduciary duties. We have assumed that the issuance and sale of the Warrants and the Warrant Shares by the Company will not,
in each case, violate or constitute a default or breach under (A) any agreement or instrument to which the Company is subject,
(B) any law, rule or regulation to which the Company is subject, (C) any judicial or regulatory order or decree of any governmental
authority, or (D) any consent, approval, license, authorization or validation of, or filing, recording or registration with any
governmental authority.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have further assumed that: (i)
the Registration Statement and any amendments thereto will have become effective under the Securities Act and comply with all applicable
laws at the time the Warrant Shares are offered or issued as contemplated by the Registration Statement; (ii) if required by law,
an appropriate prospectus supplement, free writing prospectus or term sheet relating to the Warrant Shares offered thereby will
be prepared and filed with the Commission in compliance with the Securities Act and will comply with all applicable laws at the
time the Warrant Shares are offered or issued as contemplated by the Registration Statement; (iii) all Warrant Shares will be issued
and sold in compliance with the applicable provisions of the Securities Act and the securities or Blue Sky Laws of various states
and in the manner stated in the Registration Statement and any applicable prospectus supplement; (iv) any purchase, underwriting,
warrant, deposit, unit or similar agreement (collectively the &ldquo;Securities Agreements&rdquo;) relating to the Warrant Shares
being offered will be duly authorized, executed and delivered by the Company and other parties thereto; and (v) the number of shares
of Common Stock offered pursuant to the Registration Statement does not exceed, at the time of issuance, the authorized but unissued
shares of Common Stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinions</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the foregoing and the
other matters set forth herein, it is our opinion that, as of the date hereof:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares, when issued
and sold by the Company and delivered by the Company upon valid exercise thereof and against receipt of the exercise price therefor,
in accordance with and in the manner described in the Registration Statement and the Warrants, will be validly issued, fully paid
and non-assessable</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is for your benefit
in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to
the applicable provisions of the Securities Act. We consent to your filing this opinion as an exhibit to the Registration Statement
and to the reference to our firm contained in each of the Prospectus under the heading &ldquo;Legal Matters.&rdquo; In giving such
consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities
Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P></TD>
    <TD STYLE="width: 50%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ PARSONS BEHLE &amp; LATIMER</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>tv498567_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rockville, Maryland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation
by reference in the Prospectus constituting a part of this Registration Statement on Form S-3 of our reports dated February 22,
2018, relating to the consolidated financial statements and the effectiveness of Synthetic Biologics, Inc.&rsquo;s internal control
over financial reporting, appearing in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2017. Our
report contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us
under the caption &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 20%; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ BDO USA, LLP</FONT></TD>
    <TD STYLE="width: 80%; line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">McLean, Virginia</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 107%">August 1, 2018</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tv498567_ex5-1bimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498567_ex5-1bimg01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ? !] P$1  (1 0,1 ?_$ ,    $#!0$!
M       %!PD! @0&" ,* 0 " P$! 0              ! $" P4&!Q    4#
M @,% @@'"P@+     0(#! 41!@< ""$2"3%!41,4D19A(M*3HQ55)G&!,D*S
M-&:AL5(C,R14=$5U.?!#1(2T-1D*P='Q8H)39*4V1BD1  $$ 0,!!@() @8#
M      $ $0(#!"$Q$E%!82(3% 5Q,O"!D;%2<G,T%<$DH=$C,U-C\4)B_]H
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M?XN_LU"$KHW#-^FD1^LE_P!?AN'(3^@SH4[*5H.LUJI&^L> #U$<T\/[1/\
MH@TI@_LJOR!-Y_[VW\Y46")0\LO ._X>\?'3247I0/ /8&M([+,[JE \ ]@:
MLH10/ /8&A"*!X![ T(10/ /8&A"*!X![ T(10/ /8&A"*!X![ T(10/ /8&
MA"*!X![ T(10/ /8&A"*!X![ T(0B >;V=X_OZ$)71 /3R(4X>MAN'^H3HZQ
M6JDUZR'^(CFG^\#=]/\ ,AI3VTCTE8/X NSG"HY-A8<N145Z _Q1>T?RN/\
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M'$;K:7>/\BL8=*<>6'=C&-$_,HZ=V[*%3*@;@"GF CR  A2@CPUM_*T?1_\
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MWL&$9@<]@OH<Q3ES/V0MY=W;>,@;(K22V_(SLS#HY 6LQBP8MH!-,P(O1?\
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M-QZZ)  1@!WKL9@_O;?U"HU[/>W>PEFCVPGL^C=+%NX6;GM9T^1DTF1Q.1V
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MI?4$W97IU/6V(+JS+-R>,5[UN=DXA)-PF6.;1;*163;IE7,H5(J:P$#EXT$
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M^4/'CK6&;5,Z$+B^FL3/&,F=VLHDX57!,B8&5.;F*X64"JXG$>(U-X\=.1E
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M$. E[ UG;@0,=E>$R#J>Q>C&^+PCIX]S,;LGVTZJ@5BO)DD7(.G#$!$_DJ+
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MYM8>:L.9Z%2M=8GW:_XA69O5^\/J?K >?R?*\FOE$YO*KQY/"NEL'EZ*K?\
MVPNAG/ZRWIS*BK-[G^6G7WHK\>M/*I^5W::\7>E=4%]T*!3WJ^CUK'DW:I5?
MNA^U7T>K>/O0C[H?M5]'H\?>A'W0_:KZ/1X^]"/NA^U7T>CQ]Z$?=#]JOH]'
MC[T(^Z'[5?1Z/'WH1]T/VJ^CT>/O0C[H?M5]'H\?>A'W0_:KZ/1X^]"/NA^U
M7T>CQ]Z$?=#]JOH]'C[T*T/=#S?_ +5]%3NT>/O1\$II>ZGHG_\ \J_6XC_R
)OZ)-ZYZA?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tv498567_logo01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498567_logo01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *@"+ P$1  (1 0,1 ?_$ ,@   $#!0$!
M      @ !PD#! 4&"@$" 0  !@,! 0               P0%!@@"!PD!"A
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M:5(A Y911*%())$%04# 1$ ;[=:)7;]W5?RHTZAM!M=0?D'%ME,8!U)YB,Q
MC" @;B8F%K'>GC.2QOE61NK%+WO'>5'(VJK6-D8%XM5Y*-TGLA&@X2#1 X'5
M\9(IN2B*@& >0@#'\U6U4WI76D_K=AMLZ=J=2+[+B,RDY5<%$)@#'K/;9?\
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M!E ([ZD%(-^;I2F./&VE-C-65[2VLYC9G62EKF&&U+DW4WY@F&5*E*@3%,2
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?]/R_@]Z&'A\7#^U;8/\ @[?Z?]7T<(/^G:0?LM__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tv498567_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498567_img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!- *> P$1  (1 0,1 ?_$ 0    $#!0$!
M       !!@<" P0%" D* 0$  P$! 0$! 0           0(#! 4&" <)$
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MW'T-E).\6^0<98Z:QS&\%)V=NE?- SS1[<*";)^U5CHF/;BN/-'0$-[>, [
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M*F*SI+Y2N:B#"XW<E6#F#BER[D?&$E/3-E7-<)G43+7(LNM)R1DTRI.7?\I
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M # (Z& ->K6>RD\$+17.* G*)1 I@W--W7=-IIR;#"/)6LIDEKHB*EL" '(
ME';V1S"/*83#J)C&':(UT?R5S"+E$YL-2B(D,8J9T0,4=5134TWP%38<PCNA
MM$1$ Y*I,22YBI!"'*Y$B5@ E'4"GUW2EV]EL* @4>R$0WB@.P>6N;92<Q2^
M_.()0$QCF W9 !3";42Z!L =W40 P:\H!KYM5?*E(U51+2+[N/(+V @(%$NT
MJ9-"I[@;J0ZIZ;N@ 8!Y1Y1ZHUV4:L8R%@OH@"'[D_)U^K\^J3JMNTN)QJ2C
MK1-T?6G^>/;5H:!NCZT_SQ[:@#='UI_GCVU 9  8 $ *;0W*'7^C0%!2F*!B
MD-N 8FX.ZEH.[KKH!BZ" Z]4! :C9RLI,7"COF!,#'$Q4O4%,F)B@.NH&,4P
MB4YPZAAU$.O392A%P<V [NJ8G F]N ( *9=_U0IIB(D3U\P TK):5BK%$0B*
MYRH""42B42$$@B)=3:'*/)M'01$-G((Z4ZHS+8+0YL!$#"43&*H=0#EVZ'.F
M*)Q VH#H9,1 0Y!ZVM723*:EU3-7O1;%%!, $I@(8!(!BDTY"E,7=,4 UTT,
M'*%-E*S$7WYRWS*8&'0J9!$@)B(@4IMP#<X :AM]5MUUK2[*5FSA89MGN;.N
MZ"L"B!Q.!TQ/O ;:(" &+M 0*8!* @-9-I)377E1('=-J7*R"Q*#!H(ZAOB(
MF,(DT'LC#J81]3RC6SE180R0..1,VEY<SBV8->0AP^;S#54W$W=AP$ANS+N&
MV[=T#%.&Z;>WBB!B@.H:#5FJQ/;%O$*8QQ$=3&U'=U%0O.F-N@!2CO&$QNQ
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M  \G MU)#+/PJ3^K'U1V\F(.]I?1J*NPBD7V&^G6'R>7@7#DD,M!_P#NI/\
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M@Z"4P&U/S8:%,(;X<NW;4P4(N<S^QZP?._R5M<=F,8$5RX $D^,'*14HEY=
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M["C<MX0I9Z0=.FD,@T R1SN&X**#NJ;NE 2!'\4V<+&S_G>2RIQ*XH?XHL/
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M WGOD]^&]]*RTNYC;U-,R1HCN"7\-90KVTP@W8.XX+27*H7H@$5@^L^MV<E
M;QGP+\/\;-3<DTBKH,UG)E&XGL(XNF0<P@3P.T7[R628".A7TH\1!1PIKV9M
M1ZM 3AE+".,\U^!Y<DVT2XT[#N0EV6R1TX<%!C,%9N&&\<Q1 SEJ=H[4*9$^
M\F;>U$-0 : @3]0#AI;QT9&L+7F(AO",HUG"JQ-P23-[$GC+AD;G;OF;M)4%
MBO>E918PG$1T*?=#90$IV-PS8DQ]<MHW=;$3*(W'9#2[&D%)/95V\.1*]GO2
M%Q*/"+&$CUR^=B)^<4 3 8=: 8;G@;P')VSDJT9YA<LO Y2R$GE*YTI&YY)1
M1"[6[@CE-W#+@H52,1$J14CIIB!5$M2FU : <^>>&F#SO:V+K/<W3<=DP^.+
MSAKR9FM!\K$S;AM PSJ%8,6<R7?59MUF[D05YO0QBZ@ AK0&^DN&G#LKBR)P
M\^M1NK9L0=@HFF!^;E')XQZ,DS.ZE"E!VH8D@8RINRT.<PZZZT!SQ&>33X8(
MB3GIV,CKY9W#,@SZ.GD+XE22MG'92:DL@K9;H%-^ 6[M6.)CI;3%-H.R@'!<
MGD]N'VZ6LJVE%<D'+-/(>5D@0O\ F4^Z)Z(BS0@3X)@J)$Y>2C#<V[5 -7&@
M";: #0#FL;@>X=L>0T- V];$HE'04I&S++NR=DG:Q7\7#+0"#A554XB?6,7,
M4P#L$P[W+0&TQ]PU?%SF*.R'%W(DWL6S\6/L:V-83>-5!>-8RDPG,.Y>4G%'
M"AW7.KH@4 W #=';MH#J>@"@'/;&^5\)MT?MJ1M1$- T+ZG39IR4 _1 QBAK
MH'(.FWEY?-H")K@PKBZZ+L97Q<6/K/G+NBUD5(RY)2#9/)EB#<=Y)-"053%<
M$B*!O%*(CNCR<@: 7Y;$6/KA87#$S]E6U-Q%SODI6?BY2*9NV$O*M].YY)\W
M4()5WJ12@ *#V0@ =:@*;2P]CVQR1X6=8MIVR,4D[1CCPL*RCS,R2*Q%Y4&P
MMR%%$)-5,IE@#880UH"*;8X1\06UF'(N;BVE%R^1\AST9<+RY9E@S>R4,O%P
M36!190;PZ7/M&:C1L!CAJ)A4,8=: FJ3LB'N$S16?@HF:-''6[@"59HO$VG/
MHBW<&;I+%.1(Z[<PIF$-NX(AR#0#'B^&_"$/'3<1%X>QM%1MQMBL[@8,;6BD
M&DTQ!<[CN.20YC<<M^>.8P%'80PZET&@,@W#IA4Z$2V#$V/S-X.(=V]%)K6]
M'N 9P,AMD8=,RJ1C"P>FVG(;74: S;>P1BNT0;%M3&]D6XFT>C)-B1%OQ[0$
M) 6AF(OD#)I;R+ON,W-\X40-N=CKI0%R1PICN19-XMU8=I+Q36/>QJ$:I"L3
M,B-)-QW7)-A0YH2';/W0 JLD/8'4*!A#4-: ;0\,F#!8)1(X9QKT2W?#*M8W
MP5C0:(2ADTTSR)4P1[-X8B10WS:CH 4 X5\*8U<72QOAYCJS7-XQS5)C'W0I
M!,NFV#%NB#=LT:/2)D402;H!NDTV@ <M 2NS:BW 1 1U, ;VIA$!$"D)O&T'
MLCB!-HC0&=V?[GZ- ((&'UO* [->I0%LR(&'>,4@F]=IH;S U  V!0%P2F'E
MW=.73J#U.MK0%L$A#;KMUUWMX=[341W=[EW=1Y* J%,3:".@B ::ZB'SP#0H
M_.H"@R(&,(B!.R 0/V.N^&FP#"(#L"@ B EW1U#>#4!, :;P=0I@ -I0H"X)
M3#L$0Y=1VCM\_P R@*033 !#74!\T*AS46U+%T&4J7LO952+I@ "0?@3;]L+
MIZ&SY]0FW;[,V8B>4K.963$@RJJ):?PN@:[YN2M^L5*6;69RFK6-1$1WK.A:
MJY5TKI4*=8J?O9G*3=9T4#2HV]3][,Y1=9T4#2FVJ?O9G*+K.B@:4VU3][,Y
M1=9T4#2FVJ?O9G*+K.B@:4VU3][,Y1=9T4#2FVJ?O9G*+K.BALHD=)!GV0A]
MN'9LZH%]*LWNGS+'3'JGE)@W,A*( )@U*;9J.W9M#9IU*RV:])W*()F0-P_K
M@^=_DILW=)P@W,@;A_7!\[_)39NZ3A!N9 W#^N#YW^2FS=TG"#<R!N']<'SO
M\E-F[I.$&YD#</ZX/G?Y*;-W2<(-S(&X?UP?._R4V;NDX0;F0! Q=HB&G5Y/
M2"FS=TG""9D P%T !$-IB];KZ_4ILW=)W*(-S(1S<8"$H;3DYO;6C5G,L;,F
M(GE(NLZ*&BTK7;5/WLSE%UG10-*;:I^]F<HNLZ*!I3;5/WLSE%UG1032FVJ?
MO9G*%:Q4A! $-=-HA]6L)LM)TS:.Y#?#IJ8?(60K&SD5<K[5YH&@N*U;:NQH
M@PN.%9S#)L]:R2+600!T@5^T$XHNN:5*8@J )^J&E<.)83AV*RMC629;F_X4
M7TG=A>,5^"52U6%3'2)B]!5:G,;INW;M$4FS-%-JU1)N$;(D B)=@  D3 -$
MQ#39III7HT:)1M1C$BQJ(B(N1$3)R'$ZH?4S'3<3A63'.5T9WKJBJO%$R"^K
M+RB)3(!J(B(CR;1$>41TV]>K53FU277M:B:$.:LVE6W9->Z53]!EC>0EEH3^
M3HF "]DF4=O4U -@;*S:U&-1K<B$2I:2I;9:9&I R^S_ '/T?J58N'9_N?HT
M =G^Y^C0!V?[GZ- '9_N?HT =G^Y^C0%)AT QC"&H$V=;J^CRT!&3PX?&I"#
MJ&O@M-]7J]V1?('+I0$77NYNA'*\F:WHV+D"A9C#G.[7QD#%'I40'80-@;.K
M6S/9(+ 262S:B6W+:$HB80$9A<!Y1ZQ:L!!D<F^+=L]^5_2K%WM$B])9-V?[
MN6P;;H8BDNN=(R0AM3,3L=X!-MY:J &3R@(B(6[;!0ZA2RRH%*'4*0N[V)0Z
M@4 G264/%ZV>^ZW:T!625R>4! ;<MDVWWX6#_P!&@%-*Y/-_].6R'_G*W:T!
M;&1R<(@/@[;("')_.RQOIA0%0R>3Q#0;<M8=FFV45V?.#0: 4)3)X<EMVN'F
MA++ .GSA"@$-)Y/-IO6Y;(Z?]\+!](M (62R8 __ "W;7H3*_P!4M 5#)9,$
M-/!RV_1F%M/X.M 4=(Y.Y MRV U[$V]++' 2#L,42F#3:4?0H"OI/)A2[I+<
MMP"@7< O32^Z!-=1* ;H[-: HZ1R;J'^[=L\H?\ ;"X]7K:4!<Z3R9XM6OWU
M5H"H9;)P@(!;5K (@(:A*K;/-H"STEE#Q>MGONKVM  2&2RB)B6U:Y3&]6?I
M=<5#[-H&..H"37ZW32@#I')OBW;/?E?TJ .D<F^+=L]^5_2H!RVY)90*]3#H
M"V]TR1]0Z66T .H&N@\FM /'I/*8[?!ZU]O_ 'NOVM +TEE+Q>MCOPMVE  2
M>4@U_P!W;8'77_ME<-/^+0 $GE0-@6_;'?AQZ5 4&D\ICL\'K:UZHA+K[?\
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MMNVYKU?YY5Y>K];0%/2.30,(A;EM;#I<LNOMT -.0GFT!*C>1R?S"/\ N_;
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MU!8.8)\Q2=K0!S!/F*3M: .8)\Q2=K0!S!/F*3M: .8)\Q2=K0!S!/F*3M:
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M26;(SB!L.#DL9YSB^'S%N-KO?75%O8V&D()_*RML96C!==SE&0=L6Z/=K78
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MLK[J&HOM GQ:VSUYGO[*^ZJ7V@/BUMGKS/?V5]U4OM ?%K;/7F>_LK[JI?:
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M]J74 #:')UZ !<I 4IA$VAATUW1[$VFNZ8.4#>9UZ M$?-S#IJ<O8%/J<A@
M=XYB;@<N\H!B#J :B% 5 \0$=W4W.:@'-\V?? PAJ!!V;H&$/-H"GN]K]K 5
M-!6*8R0" E%3<U Y2B8 *)R"&T-: R=\/FUK+:^0);D(JF#ATB_ !$1%4N@%
M 1Z^SS*C:>0Z9=(LRU>,PMP>MKYM=2-EPR(8K+>BJD,BE.@>9]"EV7F0K=?F
M4- \SZ%+LO,@NOS*&@>9]"EV7F077YE-1/S<3:\/)7#./4F$3%,UY!\[5UYM
M!LV(918XB #J)2$$=*O48[A>&4MR?!)B(L;/VD4^!5$RI6NH7*^K=#^6BI9#
M)8GK6FNM.]K2ON%0N"S[AB[BB710,BZBW:+D#".PQ!33,*A#I'[$X" :"%>+
M18[08Q.V,M[;=/[3V:IV\4N4DO$Z1TJGR7E:],G^)$0<VH:AV0;==3<I2B'+
MO#IH4:]&J5M!.ZLU8I!%CY?(?.HQCE7JRJLJ.73QE"OUO5 =1 0'74-FW4-=
ME5ES-I:F0W;+1?;-Y$Z=WQ_W3TJU5%3*75K6V-)/#E'S_J!4$"T 4 4 4 4
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MUGCK'L.^5@C,13I,>Y#L>U[DNV8E+[<R@O6UNN AY*,BK349G3(J#]P'J3"
M"8=E 1B_X><^.V>7<NR5I9'<9G9Y#X:%<?2KJ5N))-JQ80%OLKT)%QJ3U.,[
MC4<IK=(!S!P<#O;PB- ;3%.(K]-Q3\+=TW9A_*"N9+0RYFB<SCE*79SREKDM
MN;MR7;V8$=)O7#F&<P:C)P@@W1:$ 2+E$%-W;0$^<>_#WG/B[RFSQ=9T3;<7
MC?&6.+DNEM-Y+:RJEMRV4+J!=K;:UJ='IG.O+VAT85R0Q^Q(HL @- <NV_PL
M<3W$1?\ !97D6\C@K,EN8/Q=C28O2>9*E:S4(QF)&$RC;C=4-YRX2N2$3*LR
M-M!,YQ-0$?8IX)N(VU"XKL?#]O)8M&TI7B_;0$K=UDM;EA&T=<I(5"UU'K9Z
M<C<C6\C)*&*X -[>$3:[* ]H.!6/<6IPS6%CIY8EU8UD\:LG%HS=MW2F8[E&
M::K&Z;<Q#L^^D_AY-\!EFAT3'331/N:AR4!UT'(&FH!U 'E#S_-H!T6TH4K]
M8PB.G,<NG6#;]*@'824;G()TM]4A3"3>324, F+J @70.R$!*(#IU0H!K2]R
M6\D]:PKF78-)><2<IPT>Y<D(]E 3("KQ2.:',"[@&95/M@D 0)LUH#RB3X/N
M(,ML1_#*[;6 &&H?-B^7TLN=).5+W&(6NIS>:$&6WU$0!*74DENY#NQ-H"6F
MW0* CFY. #-L1P\)8\QI%XQ"XKFRYEBYLHK*M8E:YKDMN[IVXG]K(M;KN:)F
MNYG$(M(-C.M2&,"1#)HB Z#0$U>3_P"#S+W#-*M)+*TO%RZH\/\ C[&#IPPD
M5Y-RI,V?-2LF[<[SM(Q5&)47Y0*8=W4@:  :: !SS'\#5I-<FV=;]SR&#Y+(
M:N5>(;)MQ6^\EV:MT7)9N2[9=1=H,S1Y@5=ORLY$"K&;J""*92B8FZ(:T Q6
M_ -FRW4K=L"<F,<3,U?=N8YA+>R!*W,NVO+#OQ;W<]GYA#%[ =YU)MW,.Y3
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M)MRU'#)KFR\H5C:I[R;-Y*Y[#A[%D;J2:WDW-&G-$'19H%504(;1RL;8.Z%
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M)_#+0$<7'_2A_N7U* T% % % % % % % !_K/NB- 3&A_$(_<D_X 4!=H H
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M1-W$@/=[#8.Q3;L\ZI5K&6,6*&]QK7+=XUB2>&W7S_I  5!(M % % % % %
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M .A<H>.$)WB/[JH Z%RAXX0G>(_NJ@#H7*'CA"=XC^ZJ .A<H>.$)WB/[JH
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M+(?CC"=Y3^ZZ .@LB:B'AA"ZARAT*IL\_P#E>R@#H/(?CC"=Y5/== 4!"9%
MYO\ ?&%]4B(?S(IR!IUG>WEH"5$(3)P() 2\(3=!,FG\QGY-T/\ K58.]I22
M[T+E#QPA.\1_=50 Z%RAXX0G>(_NJ@#H7*'CA"=XC^ZJ .A<H>.$)WB/[JH
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MJ1]#Z= 6>301V!O%_A!0F"D?7$(#*&$!U#F]-0Y.2K-RH2K7(D518&BK8H%
M% % %1%(PC:727,7(U>0U4M/0D W1>3LQ&0K9T]0C$W,J^;,457[G7N9B"KI
M1,IW2XE'<3UWC:; K9DB<^QC'*NA%4JK7-]I(&VTT+OAH*>S0X:;@@/J1 P=
MB("%9/39^W9Y2J*BY%$'U>O4^T[>IR%JB39;E@UR*OE+(URY$527VHZMD!#:
M I$_@A6;LH@J6+E+]0 H H H H H"@>4?L!^G0$:._[587^J\W_KD50#,G/[
M69O^HS#_ &K7;*_TB5-T-<S\I5!*S)"@"@.9N)?B6:<,5IGO^>Q;D._[5C4!
M7FI&Q&K%^$(@HX1:;TFS>+H"J915<G-;FH@.M :RS.,3#MPKM;?NZ14Q=?QD
M&\J?'.0%46]TLXMY'IR;&:DQ8$=,X]J\8G!0O/'*70.O0#A+Q:\.BEL2UZ%R
MY;"D%$S;6W9"60!^!$9=]OBS8C'D8'EC=T%()DUB)&24 -2FTH"/W/'KPP-,
ME6!C,,AM5W^6+2FKOM&<8(.92V"1\*Z2CGJ+I^FT%5NNF^6 #%4*44]1WM*
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M(XP[GU]E=ZDRD<-9=QDE(PJ<];LUD&+1CVT_'*FU3,HLU<K@A(N6_P!L2(<
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M?=%WPV,V47;(8XLQ*#N6ZH*W'"-HL+=MA(LHE:Q;C*L":KYH1X (H"0I3*'
M -MH!VX;N'A,S9;MRW-B&UH1XOBV7NRY7D$[AE(28MZ[+N@5G<@_>Q:BBQT
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M@L$0R?B-$Y4@H^OVA?!#I]KXG,1!M'7_ '@)M'9UB!7/U&KS.Y%U#M"C3]Y
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MU'Y[3Z*4D);4T&>'('G!5C06@"@"@"@"@*!Y1^P'Z= 1H[_M5A?ZKS?^N15
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M0!TSDSQ1B>_B?L- '3.3/%&)[^)^PT =,Y,\48GOXG[#0!TSDSQ1B>_B?L-
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MWFKRMG&D!$6ED-CE&W\$WDXN&2/+/+LL1JNL\&[8U-DJA'LW_,&,B9(3COD
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M1O9U=L3>T"RN/']]3(RT]>$<YB+FLB+1C2JV]'-'R4<\CW)4MY))7>W#;-!
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M 4 @\GHA],* 0W('V1/X9: CBX_Z4/\ <OJ4!H* * * * * * * #_6?=$:
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M<:3'-WW+"P$'=UHW1;D2]FIAK;8I*7#./Y=:15!BHU4 C=<FX8O8FH#Z"#%
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MH[PCMUVT!02+13$1(L<N\&@@ [---WL0WM"ZAUMM 7"1C=,H$U$2@0$RE$=
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M6#L4C.MWGFKYN10H]0Q0H#?A=,P773%MQ]D4A#"*T:)C$3TYLAC"ZWC$)IL
M=0 * J-=LX8-!QC<X!O%/V+B/)H).33==AH \@@&PP<M :"Z#M[U8MHN[<*R
MEQ1K.483;9A+%BGC1&6BG*;R-?E05<F3[I8NT2J)&T[ Y0$-H4!OQNR;'EQA
M<VF@%W>Z(\"[I1 Q0W0=Z:%$-@=2@*S7A/&TWL8W,.AM\!%>.U*<--#E'NK4
MIPTY0VT!84O&<%4X_%C<X&43,0YB.&!#"!QWC#J5V&APTU W*'7H"DESRA3#
MS6+[@+O',N8.<C-#*J"!CF,'=.TRAP 3>N-M';0 :[)K0A!Q?<IP((F$#K1Q
MM3FT[,P"[T.;S]: ;K!./C+FFKRB\*R3"Z;B39I3\XV+%)2,P2/!4K$'ZX.0
M,X%J18Y2";40*;3DV4 Y0NJ:U WQ87*.FZ(!S\<!-2Z[HB3NO<$2@.@;.2@-
M/<;GPM@Y"V[DP_/3$)*M3,I!@\5CU$G34^G.)*#W6!P X!MT$!$* V$'.O;:
MB8^!@,23L1#135%C&QC$8M!FR:-TRI(-VR!'($223(4   "@-H:^+C-L'&ES
MB&NO\=&\OMJ@#PXN0 T^+6Y]/NT;[IH!?#FY-GYM;GV<GVZ,V=3_ $F@$&^+
MD$-!QK<XA]VC?=- 'AQ<FFGQ:W/I]VC?=- )X;W'^C2Y_O\ &^ZJ J\.;D'8
M.-;G^_1ONF@*?#>X_P!&ES_?XWW50%7AS<OZ-;G^_1ONF@#PYN3]&MS_ 'Z-
M]TT!&<M>=P"_=B&.+G[)4H#]MC1V;0#_ *56[*F=+]A8>9#5)TQ$@BV&N&\[
M@ 1_-W<O*/US#ZCK2LUF/58JMJG.LMBK%4M$\-+@_1W<O[YA[JIM'YR-E+S!
MX:7!^CNY?WS#W53:/SC92\P>&EP?H[N7]\P]U4VC\XV4O,+X:W!N[OQ=7'IK
MK_V?K\_NG6IVTS9NE1_EN2U,YHWU/9L#PTN#]'=R?OF'NJL&RV,I>I-_\-&-
MWRK'RFKY\QZ0<MGD03PSN#]'5R?OF'NJNY*VI1J-1WJHD,B9#-JJWV1#WG/B
M37XN[E ==FUCIU->1U6$R:^:D'K%"RS'N2"K8;*,O>XPD&.F.+H, '#40/'%
MTZ^PSK8.RL6L:R-U(1*0@28%\W'IJ&-KH':.NJT;YG_6:L!?#FY?T:W/]^C?
M=- 'AS<OZ-;G^_1ONF@#PYN7]&MS_?HWW30!X<W+^C6Y_OT;[IH \.;E_1K<
M_P!^C?=- 'AS<OZ-;G^_1ONF@$&^;ETV8UN?79_RT9U!_P#:J #WS<>P/BWN
M?3>+J/.QNS0=?]*\R@(]N&];C-*&$<;W0 <UZH5(X2_0<ZT!I/#2X/T=W+^^
M8^ZJ /#2X/T=W+^^8^ZJ /#2X/T=W+^^8^ZJ /#2X/T=W+^^8^ZJ /#2X/T=
MW+^^8^ZJ /#2X/T=W+^^8^ZJ /#2X/T=W+^^8^ZJ 4+RN 1-KCBZ! %$0#[;
M' &S3:'\IZNM 2NWOFY001_-M= _:B;16C-?4A_UD* O>'-R_HUN?[]&^Z:
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M BC)>?\ %N-+9)>\W=42_MLES6[:BKJV'K2?63G+JE"P\2T<I,%UNYP.[6(
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M-1'T: F%NDF""( 4/XI/^ % 7>;)ZT* .;)ZT* .;)ZT* .;)ZT* .;)ZT*
M.;)ZT* I,0FTHD*(;HCR?-LH"-792_&I"AN$VVM- .S;H#V*$-OGT SYS^UB
M<_J+'_[4K9GLD&YJP*1,0H&.)B"4NI VB4>Z 145YM01T*FD4A $3Z\HZ5B[
MVB3(8'(H= Q%$5$NZBJ<\0XJ )RI$, HE*'-JH=CV0"/+50>05I<%.4$[APL
MI>EN6K/V]8W&!F+--QLI%^P?(*67=D?S=N/DH]8!3</4W?9'+NF%   1UH"'
MXO@.S#;N8KRDBVO/7K./<MWGEG%>3B9+@8VP8(LPP6:PK*?LA.'\(I 8)!4C
M<&I%P:*H 4="[PC0$,./)Z<4UV*WY+2UE-6DE)8?M"%5BYZ\+3FHJ[+_ +8O
MU2ZG9K9AX2-18VQ;S]B )H \,J=(QQ*8PZ4!T+DG@BR3F".XE[BD,-V/:4]E
M^-P*WM:"DI.$<K6YX .CC=,022CD2HLA H@9(C;<%7?T-K0&MSWP'9PG\NWA
MD*Q8Q(N/X[*EC7]'8NL>X8:S7E[-&-A*VQ<2C,%63N&833)]HON.4#$7*7E$
M=H ):? 9<#)_=8&QI!0#&Y.&#)EBV39V1+[A[XNZ!OBX[B>R!EPE.Y6Z)&R?
M.IJ;[9'<::@4@T!:BL(\0W#LTR>U^+)A/2F>K"P;CICE6!D8M5_9$[%VT-L7
M>WE2&3"63C^Y#'5,[ Y2&(&W;0'2-Y<"K;(.>L7R:5TW' X&M/AI4P^_/8%W
MI0[VZW/2D."D1+I$;N"/8)TV:G.=0HASIE![*@(SG_)[W&&,^,^S;%A;=L"2
MRG==BKX<F8J09)2I;)LJ-MQJG:S^8,DLI;[>33BU&A1#4NBW9 (:T!&[O@<S
M:SQ;>-YXFQ[+8TXF[:N:S[JQD?(638>[8J9F(F-);DX1)S;D9'1\+%*0CA<F
MZ!#"N)""IM&@,/)7D\[^836/':<%<^5[,4P>ULR\;7L+($)8KV)O^8FEKHO*
M\% EXY^#N.GIQV<CA1#<62!,NX(T \8S@'R1%V+?W<%J6I'WK+\3.(LBP$VM
M--9:X6./+,@+6CYE(URF2*[<2,:VCW:0(DW!=B&TNAZ T\#P6Y_/ 8XQF6Q+
M:L%KC+.>8[LD<HP4W"%+<5N9'A91.W)]"-:(H3)9AJZDBB[;K:F2W1$O)0#-
MN?@(XA<BV2UM/XK[+L-SC[#26*'2S6XXUVAG=Z\NYE+N+JEP9ID%!DBS0,XW
MG@'7%<XE 0H#TIX?<"W%B+B"SW>8P]OP>,\@V[B:/M-K;Y&3=N>5LVWR1-RO
M9&"9)D;->Z'8[I=F\80WA$: XC>\&>=WZQK'6LBV>XHG*64LHJYZZ:C5I:_+
M?O>(>-H.Q9&-42":%NHY5!%R"YC($2( @ 4!Z(\)&/R8>X:<4XXE64!%RUI6
M>A$7 2W',:I$DE6CH5'2JBS($VX<RIZHXCSFG+0'1K%^RDV:+^.=(/F+E/GF
MK]FLFZ8N4R'!)<R#A(QBJI)*>J,')0&9YP@(=<.0?-#S!H!T6M_2+C[B7Z5
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MW_D[/6.CS\]PZ7WC7+ HQ=V1=_W#/A 6I*2P&;H+-I6TKK62;2!3%^WM1,H
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MSQ"-81Q>+:R"EG7%P2KJ%96G*>$4@ZCR1IEYIM-)KMW+I-N0.;<#]M(.F@[
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M:"<0DF)=\P!H)Q %>40"@+OA-;WO]"]]&?LM 'A-;WO]"]]&?LM 'A-;WO\
M0O?1G[+0!X36][_0O?1G[+0!X36][_0O?1G[+0!X36][_0O?1G[+0!X36][_
M $+WT9^RT >$UO>_T+WT9^RT >$UO>_T+WT9^RT >$UO>_T+WT9^RT >$UO>
M_P!"]]&?LM 'A-;WO]"]]&?LM 1;+7';HR#\>GH;:J ?TFTZH?=.6@-;X26Y
M[_0_?-G[)76E.Q418J!/".W_ '[BN^#4?_[E3U>7G4!X26YU9V'#SY)I[)3J
M\O.H#PDMSW^A^^;3V2G5Y>=>8&.[F;3?-UVCN8@W#9T@NU=(*R#(Z;AJY2,D
MH@H4RFFX(&$?/IU>7G4%#"4L^+;(LH^4@&;-L4"-VC=^R2;I$#D*"1% (.G7
M&G5Y>=0987%;8:Z3L0&HB8?YT:CM'K:J[ \SDIU>7G7F!0>X[<V?S]#];^DV
MG5_^\\RG5Y>=0;F,N6WBR$?I.0Y@W]H])L^K_P#>]2L)K$EJB)F!)P7+;^T1
MG(<NH_72C,-=- U#[;R5D!?":WO?Z%[Z,_9: /":WO?Z%[Z,_9: /":WO?Z%
M[Z,_9: /":WO?Z%[Z,_9: /":WO?Z%[Z,_9: /":WO?Z%[Z,_9: /"6WAV=.
MPO?1GU-O_.T AKDM_0/Y\AM-XNO\YL_7!_ZWKT!'-Q7);HRA_P"?8?8G[Y-.
MJ _^M'K59B(YR-7(H-#X26Y[_0_?-I[)75U>7G7F >$EN>_T/WS:>R4ZO+SK
MS /"2W/?Z'[YM/9*=7EYUY@'A);GO]#]\VGLE.KR\Z\P#PDMSW^A^^;3V2G5
MY>=>8!X26Y[_ $/WS:>R4ZO+SKS /"2W/?Z'[YM/9*=7EYUY@+X1VZ8?Z>AM
MBB.G\YL]>I_ZVG5Y>=02ZVN>WC-T1Z=A?XHG_:C/J% /^=KE>EURM3B4%_PF
MM[W^A>^C/V6J@/":WO?Z%[Z,_9: /":WO?Z%[Z,_9: /":WO?Z%[Z,_9: /"
M:WO?Z%[Z,_9: /":WO?Z%[Z,_9: MGN:W@WA"<AQ$"=249Z:;?\ UO+0$=.9
MZ(/E")7+)QQDDK5F#J*D?-C))@=_%$+SJI5!(EO&$ +J(:CL"@&==MO04SE>
M4-*1+-\=.S&0$.X3W]W^=M V#L'36MVY"!0L.S_KK:A1'40$>X$MN@B%2!?
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M^E4;3^)1%2SX!V;XLPOM!'TJG;+G4@<MKV#9IGYRFMN(-S20B'\C2#7>U'D
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M9M!/N\\JJ0J+<YMTQ]0H#M".E&\FF59J)5&ZB95D%RFU(ND?=%-1/8 [ABF
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M]9]T1H"8T/XA'[DG_ "@+M % % % % % 4#RC]@/TZ C1W_:K"_U7F_]<BJ
M9DY_:S-_U&8?[5KME?Z1*FZ&N9^4J@E9DA0!0!0!0!0!0!0$ \4>$4.)' N0
M<'.I9*#9Y 8LHYW)+M#/4D&[60;OE ,W(8BAQ5*AN;#!ZK;LH#G3+GDZ<"92
MM'#6-SV99L'C['U_M;YO"U&<'S4=?#EM:4A;!C#S)RK-'QN[07*H<QBE.34
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M_!5T&E\#JY,AKUQS=EW0AK_R$?)B,>M*9-7N)$ZK)W+/YMH91<AM! A]TH
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M/X9: CBX_P"E#_<OJ4!H* * * * * * * #_ %GW1&@)C0_B$?N2?\ * NT
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MGW^B?;S?V2@#PKMGW^B?;S?V2@$&Z[9]_HGE#_IS?J#KZ^@*3W9; %U&?B0
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MO]$<NNV@*@^)_0-/ K3J:=$Z>AI0%'YF_P A_P $4 ?F:_(?\$4 ?F:_(?\
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89N=';O,]U-N;Y[=['<[IW--[Z[32@/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
